β-Arrestin-1 Inhibitors are a class of compounds that have garnered significant attention within the realm of cell signaling. These molecules are specifically designed to modulate the activity of β-arrestin-1, a key intracellular protein involved in regulating G-protein-coupled receptor (GPCR) signaling pathways. GPCRs, a diverse group of cell surface receptors, play a pivotal role in transmitting extracellular signals to intracellular responses. β-arrestin-1, traditionally considered as a terminator of GPCR signaling through desensitization and internalization, has now been recognized for its role in initiating alternative pathways, distinct from those triggered by G proteins. β-Arrestin-1 inhibitors operate by selectively binding to β-arrestin-1 and inhibiting its interaction with GPCRs, effectively dampening or redirecting downstream signaling cascades. The design and development of these inhibitors require a deep understanding of the structural and functional aspects of β-arrestin-1 and its interactions with GPCRs.
Researchers have employed various strategies, including virtual screening, structure-based drug design, and high-throughput screening, to identify compounds that can effectively hinder the association between β-arrestin-1 and GPCRs. Mechanistically, these inhibitors can modulate signaling pathways by preventing β-arrestin-1-mediated internalization of GPCRs, altering receptor trafficking, and impacting downstream signaling effectors. In summary, β-Arrestin-1 inhibitors represent a fascinating class of molecules aimed at elucidating the intricate complexities of GPCR signaling. By selectively targeting β-arrestin-1, these inhibitors provide researchers with a valuable tool to dissect the specific contributions of β-arrestin-1-mediated pathways in cellular responses. As the understanding of GPCR signaling continues to evolve, β-Arrestin-1 inhibitors hold the promise of offering insights into novel signaling paradigms, beyond the canonical G protein-dependent pathways, ultimately contributing to a more comprehensive comprehension of cellular communication and signal transduction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bakuchiol | 10309-37-2 | sc-202075 | 1 mg | $45.00 | 1 | |
A natural compound found in plants, it has been shown to inhibit β-arrestin-1-mediated signaling pathways. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
While primarily a beta-blocker, it also exhibits some β-arrestin-1 inhibitory effects, affecting GPCR-mediated pathways. | ||||||
Dexrazoxane | 24584-09-6 | sc-252669 | 5 mg | $112.00 | 1 | |
An agent with potential β-arrestin-1 inhibitory effects. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
A beta-blocker with partial agonist activity, affecting β-arrestin-1-mediated signaling along with GPCR pathways. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
A non-selective beta-blocker with antioxidant properties that can influence β-arrestin-1-dependent signaling. | ||||||
IC261 | 186611-52-9 | sc-3561 | 5 mg | $140.00 | 11 | |
An ATP-competitive inhibitor that disrupts the activity of protein kinases, potentially impacting β-arrestin-1 pathways. | ||||||
PF-3644022 | 1276121-88-0 | sc-478487 sc-478487A | 5 mg 25 mg | $367.00 $2856.00 | ||
An experimental compound developed as a β-arrestin-1 inhibitor, targeting its interactions with GPCRs. | ||||||
Ambrisentan | 177036-94-1 | sc-207276 | 5 mg | $348.00 | ||
While primarily used for pulmonary arterial hypertension, it has been investigated for its effects on β-arrestin-1 signaling. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
A natural polyphenol with potential β-arrestin-1 inhibitory effects, although its precise mechanism is still under study. | ||||||